CRISPR Therapeutics to Attend Future Investor Conferences

CRISPR Therapeutics, a renowned biopharmaceutical company based in ZUG, Switzerland, and Boston, announced today its participation in key investor conferences slated for June 2024. This company, known for developing groundbreaking gene-based treatments for serious illnesses, will have senior management representatives present at two pivotal events.

The first event is the Jefferies Healthcare Conference, scheduled for June 5, 2024, at 10:00 a.m. ET. The second is the Goldman Sachs 45th Annual Global Healthcare Conference, set for June 11, 2024, at 9:20 a.m. ET. Attendees and interested parties can access a live webcast of these presentations on the "Events & Presentations" page in the Investors section of CRISPR Therapeutics' website. Webcast replays will be available on the company's website for 14 days post-presentation.

CRISPR Therapeutics has seen a significant evolution since its inception over a decade ago. Initially a research-stage company, it has now achieved the historic milestone of getting the first-ever CRISPR-based therapy approved. The company boasts a diversified portfolio targeting various disease areas, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular diseases, autoimmune disorders, and rare diseases.

In 2018, CRISPR Therapeutics made headlines by introducing the first CRISPR/Cas9 gene-edited therapy into clinical trials, targeting sickle cell disease and transfusion-dependent beta-thalassemia. By late 2023, their product CASGEVY™ (exagamglogene autotemcel) received approval in specific countries for treating eligible patients with these conditions. The CRISPR technology, recognized with a Nobel Prize, has revolutionized biomedical research, offering a validated approach with the potential to create transformative medicines.

To propel its mission forward, CRISPR Therapeutics has formed strategic partnerships with leading companies such as Bayer and Vertex Pharmaceuticals. These collaborations aim to accelerate and broaden the scope of their pioneering efforts in gene-editing therapies.

CRISPR Therapeutics AG, headquartered in Zug, Switzerland, operates through its fully-owned U.S. subsidiary in Boston, Massachusetts, with additional R&D activities in San Francisco, California, and business offices in London, United Kingdom. For more information, individuals can visit CRISPR Therapeutics' official website.

The company remains dedicated to its vision of transforming the treatment landscape for serious diseases through innovative gene-editing technologies. As it continues to advance its portfolio and collaborate with industry leaders, CRISPR Therapeutics stands at the forefront of biopharmaceutical innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!